This page has only limited features, please log in for full access.
Lung cancer is characterized by a tremendously high mortality rate and a low 5-year survival rate when diagnosed at a late stage. Early diagnosis of lung cancer drastically reduces its mortality rate and improves survival. Exhaled breath analysis could offer a tool to clinicians to improve the ability to detect lung cancer at an early stage, thus leading to a reduction in the associated survival rate. In this paper, we present an electronic nose for the automatic analysis of exhaled breath. A total of five a-specific gas sensors were embedded in the electronic nose, making it sensitive to different volatile organic compounds (VOCs) contained in exhaled breath. Nine features were extracted from each gas sensor response to exhaled breath, identifying the subject breathprint. We tested the electronic nose on a cohort of 80 subjects, equally split between lung cancer and at-risk control subjects. Including gas sensor features and clinical features in a classification model, recall, precision, and accuracy of 78%, 80%, and 77% were reached using a fourfold cross-validation approach. The addition of other a-specific gas sensors, or of sensors specific to certain compounds, could improve the classification accuracy, therefore allowing for the development of a clinical tool to be integrated in the clinical pipeline for exhaled breath analysis and lung cancer early diagnosis.
Davide Marzorati; Luca Mainardi; Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari; Pietro Cerveri. MOS Sensors Array for the Discrimination of Lung Cancer and At-Risk Subjects with Exhaled Breath Analysis. Chemosensors 2021, 9, 209 .
AMA StyleDavide Marzorati, Luca Mainardi, Giulia Sedda, Roberto Gasparri, Lorenzo Spaggiari, Pietro Cerveri. MOS Sensors Array for the Discrimination of Lung Cancer and At-Risk Subjects with Exhaled Breath Analysis. Chemosensors. 2021; 9 (8):209.
Chicago/Turabian StyleDavide Marzorati; Luca Mainardi; Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari; Pietro Cerveri. 2021. "MOS Sensors Array for the Discrimination of Lung Cancer and At-Risk Subjects with Exhaled Breath Analysis." Chemosensors 9, no. 8: 209.
Despite there already being many studies on robotic surgery as a minimally invasive approach for non-small-cell lung cancer (NSCLC) patients, the use of this technique for stage III disease is still poorly described. These are the preliminary results of our prospective study on the safety and effectiveness of robotic approaches in patients with locally advanced NSCLC in terms of postoperative complications and oncological outcomes. Since 2016, we prospectively investigated 19 consecutive patients with NSCLC stage IIIA-pN2 (diagnosed by EBUS-TBNA) who underwent lobectomy and radical lymph node dissection with robotic approaches after induction treatment. Furthermore, we matched a case-control study with 46 patients treated with open surgery during the same period of time, with similar age, comorbidities, clinical stage and tumor size. The individual matched population was composed of 16 robot-assisted thoracic surgeries and 16 patients who underwent open surgery. The median time range of resection was inferior in the open group compared to robotic lobectomy (243 vs. 161 min; p< 0.001). Lymph node resection and positivity were not significantly different (p = 0.96 and p = 0.57, respectively). Moreover, no difference was observed for PFS (p = 0.16) or OS (p = 0.41). In conclusion, we demonstrated that the early outcomes and oncological results of N2-patients after robotic lobectomy were similar to those who had open surgery. Considering the advantages of minimally invasive surgery, robot-assisted lobectomy appears to be a safe approach to patients with locally advanced diseases.
Monica Casiraghi; Francesco Petrella; Giulia Sedda; Antonio Mazzella; Juliana Guarize; Patrick Maisonneuve; Filippo De Marinis; Lorenzo Spaggiari. Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study. Journal of Clinical Medicine 2021, 10, 3465 .
AMA StyleMonica Casiraghi, Francesco Petrella, Giulia Sedda, Antonio Mazzella, Juliana Guarize, Patrick Maisonneuve, Filippo De Marinis, Lorenzo Spaggiari. Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study. Journal of Clinical Medicine. 2021; 10 (16):3465.
Chicago/Turabian StyleMonica Casiraghi; Francesco Petrella; Giulia Sedda; Antonio Mazzella; Juliana Guarize; Patrick Maisonneuve; Filippo De Marinis; Lorenzo Spaggiari. 2021. "Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study." Journal of Clinical Medicine 10, no. 16: 3465.
Lung cancer is the leading cause of cancer deaths worldwide. Its early detection has the potential to significantly impact the burden of the disease. The screening and diagnostic techniques in current use suffer from limited specificity. The need therefore arises for a reliable biomarker to identify the disease earlier, which can be integrated into a test. This test would also allow for the recurrence risk after surgery to be stratified. In this context, urine could represent a non-invasive alternative matrix, with the urinary metabolomic profile offering a potential source for the discovery of diagnostic biomarkers. This paper aims to examine the current state of research and the potential for translation into clinical practice.
Roberto Gasparri; Giulia Sedda; Valentina Caminiti; Patrick Maisonneuve; Elena Prisciandaro; Lorenzo Spaggiari. Urinary Biomarkers for Early Diagnosis of Lung Cancer. Journal of Clinical Medicine 2021, 10, 1723 .
AMA StyleRoberto Gasparri, Giulia Sedda, Valentina Caminiti, Patrick Maisonneuve, Elena Prisciandaro, Lorenzo Spaggiari. Urinary Biomarkers for Early Diagnosis of Lung Cancer. Journal of Clinical Medicine. 2021; 10 (8):1723.
Chicago/Turabian StyleRoberto Gasparri; Giulia Sedda; Valentina Caminiti; Patrick Maisonneuve; Elena Prisciandaro; Lorenzo Spaggiari. 2021. "Urinary Biomarkers for Early Diagnosis of Lung Cancer." Journal of Clinical Medicine 10, no. 8: 1723.
Our goal was to assess the safety, feasibility and oncological outcomes of non-intubated thoracoscopic lobectomies for non-small-cell lung cancer (NSCLC). A comprehensive search was performed in EMBASE (via Ovid), MEDLINE (via PubMed) and Cochrane CENTRAL from January 2004 to March 2020. Studies comparing non-intubated anaesthesia with intubated anaesthesia for thoracoscopic lobectomy for NSCLC were included. An exploratory systematic review and a meta-analysis were performed by combining the reported outcomes of the individual studies using a random effects model. For dichotomous outcomes, risk ratios were calculated and for continuous outcomes, the mean difference was used. Three retrospective cohort studies were included, with a total of 204 patients. The comparison between non-intubated and intubated patients undergoing thoracoscopic lobectomy showed no statistically significant differences in postoperative complication rates [risk ratio 0.65, 95% confidence interval (CI) 0.36–1.16; P = 0.30; I2 = 17%], operating times (mean difference −12.40, 95% CI −28.57 to 3.77; P = 0.15; I2 = 48%), length of hospital stay (mean difference −1.13, 95% CI −2.32 to 0.05; P = 0.90; I2 = 0%) and number of dissected lymph nodes (risk ratio 0.92, 95% CI 0.78–1.25; P = 0.46; I2 = 0%). Despite the limitation of only 3 papers included, awake and intubated thoracoscopic lobectomies for resectable NSCLC seem to have comparable perioperative and postoperative outcomes. Nevertheless, the oncological implications of the non-intubated approach should be considered. The long-term benefits for patients with lung cancer need to be carefully assessed.
Elena Prisciandaro; Luca Bertolaccini; Giulia Sedda; Lorenzo Spaggiari. Non-intubated thoracoscopic lobectomies for lung cancer: an exploratory systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery 2020, 31, 499 -506.
AMA StyleElena Prisciandaro, Luca Bertolaccini, Giulia Sedda, Lorenzo Spaggiari. Non-intubated thoracoscopic lobectomies for lung cancer: an exploratory systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery. 2020; 31 (4):499-506.
Chicago/Turabian StyleElena Prisciandaro; Luca Bertolaccini; Giulia Sedda; Lorenzo Spaggiari. 2020. "Non-intubated thoracoscopic lobectomies for lung cancer: an exploratory systematic review and meta-analysis." Interactive Cardiovascular and Thoracic Surgery 31, no. 4: 499-506.
Objective Tracheal sleeve pneumonectomy is a challenge in lung cancer management and in achieving long-term oncological results. In November 2018, we started a prospective study on the role of extracorporeal membrane oxygenation (ECMO) in tracheal sleeve pneumonectomy. We aim to present our preliminary results. Methods From November 2018 to November 2019, six patients (three men and three women; median age: 61 years) were eligible for tracheal sleeve pneumonectomy for lung cancer employing the veno-venous ECMO during tracheobronchial anastomosis. Results Only in one patient, an intrapericardial pneumonectomy without ECMO support was performed, but cannulas were maintained during surgery. The median length of surgery was 201 minutes (range: 162–292 minutes), and the average duration of the apneic phase was 38 minutes (range: 31–45 minutes). No complications correlated to the positioning of the cannulas were recorded. There was only one major postoperative complication (hemothorax). At the time of follow-up, all patients were alive; one patient alive with bone metastasis was being treated with radiotherapy. Conclusion ECMO-assisted oncological surgery was rarely described, and its advantages include hemodynamic stability with low bleeding complications and a clean operating field. As suggested by our preliminary data, ECMO-assisted could be a useful alternative strategy in select lung cancer patients.
Lorenzo Spaggiari; Giulia Sedda; Francesco Petrella; Marco Venturino; Fabiana Rossi; Juliana Guarize; Domenico Galetta; Monica Casiraghi; Giorgio Lo Iacono; Luca Bertolaccini; Francesco Alamanni. Preliminary Results of Extracorporeal Membrane Oxygenation Assisted Tracheal Sleeve Pneumonectomy for Cancer. The Thoracic and Cardiovascular Surgeon 2020, 69, 240 -245.
AMA StyleLorenzo Spaggiari, Giulia Sedda, Francesco Petrella, Marco Venturino, Fabiana Rossi, Juliana Guarize, Domenico Galetta, Monica Casiraghi, Giorgio Lo Iacono, Luca Bertolaccini, Francesco Alamanni. Preliminary Results of Extracorporeal Membrane Oxygenation Assisted Tracheal Sleeve Pneumonectomy for Cancer. The Thoracic and Cardiovascular Surgeon. 2020; 69 (03):240-245.
Chicago/Turabian StyleLorenzo Spaggiari; Giulia Sedda; Francesco Petrella; Marco Venturino; Fabiana Rossi; Juliana Guarize; Domenico Galetta; Monica Casiraghi; Giorgio Lo Iacono; Luca Bertolaccini; Francesco Alamanni. 2020. "Preliminary Results of Extracorporeal Membrane Oxygenation Assisted Tracheal Sleeve Pneumonectomy for Cancer." The Thoracic and Cardiovascular Surgeon 69, no. 03: 240-245.
Starting from the work of Ulivi and colleagues, we aim to summarize the research area of biomarkers for early diagnosis and early stage lung cancer.
Roberto Gasparri; Giulia Sedda; Lorenzo Spaggiari. Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician’s Point of View. Journal of Clinical Medicine 2020, 9, 1790 .
AMA StyleRoberto Gasparri, Giulia Sedda, Lorenzo Spaggiari. Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician’s Point of View. Journal of Clinical Medicine. 2020; 9 (6):1790.
Chicago/Turabian StyleRoberto Gasparri; Giulia Sedda; Lorenzo Spaggiari. 2020. "Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician’s Point of View." Journal of Clinical Medicine 9, no. 6: 1790.
Lung cancer (LC) accounts for 1.6 million death each year, remaining the leading cause of oncology-related death. This worst-case scenario is linked to poor survival associated with late diagnosis. This happens commonly in clinical practice, even in countries with strong and developed health systems, resulting in a lower chance of survival and a higher cost of treatment. Ideally, screening in an asymptomatic at-risk population could increase the chance of recognition cancerous cells, or even pre-cancerous conditions, in a majority of individuals who will results negative to the test. With this article, we aim to summarize the best new approach in LC research.
Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. Translational new frontiers in lung cancer research. Shanghai Chest 2020, 4, 16 -16.
AMA StyleGiulia Sedda, Roberto Gasparri, Lorenzo Spaggiari. Translational new frontiers in lung cancer research. Shanghai Chest. 2020; 4 ():16-16.
Chicago/Turabian StyleGiulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. 2020. "Translational new frontiers in lung cancer research." Shanghai Chest 4, no. : 16-16.
OBJECTIVES A few studies have already demonstrated survival benefits for local treatment in solitary metastatic non-small-cell lung cancer (NSCLC). The aim of this study is to retrospectively investigate the role of surgery in patients with oligometastatic (OM) NSCLC. METHODS Between January 1998 and December 2018, 57 patients with OM stage IV NSCLC (1 or 2) underwent a multidisciplinary approach including lung cancer surgery, local treatment of the distant metastasis (DM) and systemic medical treatments. RESULTS All patients had DM synchronous to lung cancer. Fifty-one (90%) patients had a single DM whereas 6 (11%) patients had 2 DMs. Forty-eight (84%) patients underwent induction chemotherapy. We performed 47 (82%) lobectomies, 4 (7%) segmentectomies and 6 (11%) pneumonectomies. Pathological lymph node involvement was evident in 28 (49%) patients. Adjuvant chemotherapy was administered in 20 (35%) patients. Forty-six (81%) patients had local treatment of the DM before lung resection, and 11 (19%) patients had after lung resection; 6 (11%) patients had both treatments. The median overall survival (OS) was 30 months, with the 2-, 3- and 5-year OS of 57%, 50% and 30%, respectively. OS was significantly related to lymph node involvement (P = 0.04), size of the primary tumour (P < 0.001), neoadjuvant chemotherapy (P = 0.02) and the time period between metastasis diagnosis and primary tumour removal (P = 0.04). CONCLUSIONS Multidisciplinary approach is the gold standard in OM patients. Patients with no lymph node involvement are the best candidates, with an acceptable OS. Thus, patients with OM-NSCLC should not be excluded from surgery as a matter of principle.
Monica Casiraghi; Luca Bertolaccini; Giulia Sedda; Francesco Petrella; Domenico Galetta; Juliana Guarize; Patrick Maisonneuve; Filippo De Marinis; Lorenzo Spaggiari. Lung cancer surgery in oligometastatic patients: outcome and survival. European Journal of Cardio-Thoracic Surgery 2020, 57, 1173 -1180.
AMA StyleMonica Casiraghi, Luca Bertolaccini, Giulia Sedda, Francesco Petrella, Domenico Galetta, Juliana Guarize, Patrick Maisonneuve, Filippo De Marinis, Lorenzo Spaggiari. Lung cancer surgery in oligometastatic patients: outcome and survival. European Journal of Cardio-Thoracic Surgery. 2020; 57 (6):1173-1180.
Chicago/Turabian StyleMonica Casiraghi; Luca Bertolaccini; Giulia Sedda; Francesco Petrella; Domenico Galetta; Juliana Guarize; Patrick Maisonneuve; Filippo De Marinis; Lorenzo Spaggiari. 2020. "Lung cancer surgery in oligometastatic patients: outcome and survival." European Journal of Cardio-Thoracic Surgery 57, no. 6: 1173-1180.
Platypnea–orthodeoxia is a rare syndrome characterized by dyspnoea and arterial desaturation, exacerbated by an upright position and relieved when the subject is recumbent. We report on a unique case of a patient with severe scoliosis who presented with several episodes of arterial desaturation after right pulmonary wedge resection.
Stefano Maria Donghi; Giulia Sedda; Juliana Guarize; Lorenzo Spaggiari. Platypnea–orthodeoxia syndrome after pulmonary wedge resection in a patient with severe scoliosis. Interactive Cardiovascular and Thoracic Surgery 2020, 30, 790 -791.
AMA StyleStefano Maria Donghi, Giulia Sedda, Juliana Guarize, Lorenzo Spaggiari. Platypnea–orthodeoxia syndrome after pulmonary wedge resection in a patient with severe scoliosis. Interactive Cardiovascular and Thoracic Surgery. 2020; 30 (5):790-791.
Chicago/Turabian StyleStefano Maria Donghi; Giulia Sedda; Juliana Guarize; Lorenzo Spaggiari. 2020. "Platypnea–orthodeoxia syndrome after pulmonary wedge resection in a patient with severe scoliosis." Interactive Cardiovascular and Thoracic Surgery 30, no. 5: 790-791.
Primitive aortic sarcomas are rare tumors characterized by resistance to medical treatment and a poor prognosis with high metastatic rates and local recurrences. Surgery remains the mainstay treatment and is based on challenging and technically demanding resections with high rate of major intraoperative and postoperative complications. We report the case of a patient with primitive intimal sarcoma of the aorta, who underwent a descending aortic resection and reconstruction with a prosthetic tube.
Adele Tessitore; Alessio V. Mariolo; Domenico Galetta; Giulia Sedda; Rosa Spirito; Lorenzo Spaggiari. Primary Sarcoma of Descending Aorta. AORTA 2019, 07, 169 -171.
AMA StyleAdele Tessitore, Alessio V. Mariolo, Domenico Galetta, Giulia Sedda, Rosa Spirito, Lorenzo Spaggiari. Primary Sarcoma of Descending Aorta. AORTA. 2019; 07 (06):169-171.
Chicago/Turabian StyleAdele Tessitore; Alessio V. Mariolo; Domenico Galetta; Giulia Sedda; Rosa Spirito; Lorenzo Spaggiari. 2019. "Primary Sarcoma of Descending Aorta." AORTA 07, no. 06: 169-171.
Robotic-assisted surgery has become the first choice for several conditions since its introduction in clinical practice in 2000. However, the U.S. Food and Drug Administration has recently raised a warning against the use of robotic surgical approaches for the cure and prevention of cancer following the publication of two studies focused on endometrial cancer. We conducted an internal audit to retrospectively analyze our experience to assess the safety and feasibility of robotic-assisted surgery compared to open surgery. We selected a 5-year period to guarantee at least 2 years of follow-up (2011-2016) and identified 1139 patients who underwent lobectomy for NSCLC in our division. The primary data set analyzed included 544 early-stage clinical N0 patients (348 open and 196 robotic surgeries). We compared 131 patients of each group individually matched, with demographic and clinical characteristics almost identical. No difference was observed between the cohorts, either in terms of recurrence-free survival (hazard ratio: 1.09; p = 0.55) or overall survival (hazard ratio: 0.86; p = 0.36). The 5-year recurrence of disease risk and overall survival were 24.9% and 83.2%, respectively, in the open group and 24.6% and 86.1%, respectively, in the robotic group. These data underline that robotic-assisted lobectomy for early NSCLC is a safe and feasible technique with adequate long-term and progression-free survival compared to open surgery.
Lorenzo Spaggiari; Giulia Sedda; Patrick Maisonneuve; Adele Tessitore; Monica Casiraghi; Francesco Petrella; Domenico Galetta. A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer. Journal of Thoracic Oncology 2019, 14, 2176 -2180.
AMA StyleLorenzo Spaggiari, Giulia Sedda, Patrick Maisonneuve, Adele Tessitore, Monica Casiraghi, Francesco Petrella, Domenico Galetta. A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer. Journal of Thoracic Oncology. 2019; 14 (12):2176-2180.
Chicago/Turabian StyleLorenzo Spaggiari; Giulia Sedda; Patrick Maisonneuve; Adele Tessitore; Monica Casiraghi; Francesco Petrella; Domenico Galetta. 2019. "A Brief Report on Survival After Robotic Lobectomy for Early-Stage Lung Cancer." Journal of Thoracic Oncology 14, no. 12: 2176-2180.
OBJECTIVES The aim of this study was to assess the postoperative outcomes of robotic-assisted lobectomy in obese patients to determine the impact of the robotic approach on a high-risk population who were candidates for major pulmonary resection for non-small-cell lung cancer (NSCLC). METHODS Between January 2007 and August 2018, we retrospectively reviewed the medical records of 224 obese patients (body mass index ≥ 30) who underwent pulmonary lobectomy at our institution via robotic-assisted thoracic surgery (RATS, n = 51) or lateral muscle-sparing thoracotomy (n = 173). RESULTS Forty-two patients were individually matched with those who had the same pathological tumour stage and similar comorbidities and presurgical treatment. The median operative time was significantly longer in the RATS group compared to that in the thoracotomy group (200 vs 158 min; P = 0.003), whereas the length of stay was significantly better for the RATS group (5 vs 6 days; P = 0.047). Postoperative complications were significantly more frequent after open lobectomy than in the RATS group (42.9% vs 16.7%; P = 0.027). After a median follow-up of 4.4 years, the 5-year overall survival rate was 67.6% [95% confidence interval (CI) 45.7–82.2] for the RATS group, and 66.1% (95% CI 46.8–79.9) for the open surgery group (log-rank P = 0.54). The 5-year cumulative incidence of cancer-related deaths was 24.8% (95% CI 9.7–43.5) for the RATS group and 23.6% (95% CI 10.8–39.2) for the open surgery group (Gray’s test, P = 0.69). CONCLUSIONS RATS is feasible and safe for obese patients with NSCLC with advantages compared to open surgery in terms of early postoperative outcomes. In addition, the long-term survival rate was comparable to that of the open approach.
Monica Casiraghi; Giulia Sedda; Cristina Diotti; Alessio Vincenzo Mariolo; Domenico Galetta; Adele Tessitore; Patrick Maisonneuve; Lorenzo Spaggiari. Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer. Interactive CardioVascular and Thoracic Surgery 2019, 30, 359 -365.
AMA StyleMonica Casiraghi, Giulia Sedda, Cristina Diotti, Alessio Vincenzo Mariolo, Domenico Galetta, Adele Tessitore, Patrick Maisonneuve, Lorenzo Spaggiari. Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer. Interactive CardioVascular and Thoracic Surgery. 2019; 30 (3):359-365.
Chicago/Turabian StyleMonica Casiraghi; Giulia Sedda; Cristina Diotti; Alessio Vincenzo Mariolo; Domenico Galetta; Adele Tessitore; Patrick Maisonneuve; Lorenzo Spaggiari. 2019. "Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer." Interactive CardioVascular and Thoracic Surgery 30, no. 3: 359-365.
Background: Choriocarcinoma is a rare malignant disease that is usually associated with a gestational event. Lung metastasis with no evident primary origin and choriocarcinoma, which mimics features of non-small-cell lung cancer, might be misdiagnosed as adenocarcinoma or large-cell carcinoma. This is a pivotal clinical concern since the tumor can lead to various symptoms, seriously affecting the quality of life and can escalate rapidly, with a high mortality rate, compared to lung cancer. Methods: We reported a case of a 37-year-old woman with a history of one-year enhancement of beta-human chorionic gonadotropin levels and only a single nodule in the right upper lobe, with no abnormal findings on the gynecological investigation. Then we retrospectively examined all cases treated in the Division of Thoracic Surgery at the European Institute of Oncology in the last twenty years (from 1998 to 2018). Results: This was the first time in our experience that choriocarcinoma presentation was with a single nodule without a gynecological finding. Moreover, the differential diagnosis between lung carcinoma and choriocarcinoma was achieved only after surgical removal. Conclusions: As confirmed by our literature search, precise and expedited differential diagnosis is essential in choriocarcinoma care (both with single or multiple metastases), to successfully remove the tumor and increase the patient’s chances of survival.
Roberto Gasparri; Giulia Sedda; Daniela Brambilla; Lara Girelli; Cristina Diotti; Lorenzo Spaggiari. When a Differential Diagnosis Is Fundamental: Choriocarcinoma Mimicking Lung Carcinoma. Journal of Clinical Medicine 2019, 8, 2018 .
AMA StyleRoberto Gasparri, Giulia Sedda, Daniela Brambilla, Lara Girelli, Cristina Diotti, Lorenzo Spaggiari. When a Differential Diagnosis Is Fundamental: Choriocarcinoma Mimicking Lung Carcinoma. Journal of Clinical Medicine. 2019; 8 (11):2018.
Chicago/Turabian StyleRoberto Gasparri; Giulia Sedda; Daniela Brambilla; Lara Girelli; Cristina Diotti; Lorenzo Spaggiari. 2019. "When a Differential Diagnosis Is Fundamental: Choriocarcinoma Mimicking Lung Carcinoma." Journal of Clinical Medicine 8, no. 11: 2018.
Thymic tumors are rare diseases with an incidence of 0.15 cases per 100,000 person-years. They can be associated with a variety of other syndromes, such as Myasthenia Gravis or autoimmune disorders. Among them, pure red cell aplasia is a hemato-pathological condition characterized by anemia, reticulocytopenia and erythroid cell hypoplasia of bone marrow. Here, we reported a case of a 62-year-old female with a long history of neurologic symptoms due to Myasthenia Gravis. She was diagnosed with thymoma, with mediastinal mass and pleural thickening. After chemoradiotherapy treatment, she was surgically resected successfully, but she developed anemia and severe thrombocytopenia, worsening in respiratory failure requiring intubation. A bone marrow biopsy was performed resulting in a red-cell aplasia with marked hypoplasia of megakaryocytopoiesis compatible with pure red cell aplasia with acquired thrombocytopenia. Considering that there are no standard treatments, clinical condition improvement was achieved only after some lines of medical treatment. Our data, together with the few already published, help to raise the attention towards acquired cytopenias and the need to optimize the treatment for a potentially life-threatening condition.
Giorgio Lo Iacono; Federica Gigli; Lorenzo Gherzi; Daniele Avenoso; Stefano Fiori; Giulia Sedda; Corrado Tarella; Lorenzo Spaggiari. Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis: A rare and life-treating condition. Transfusion and Apheresis Science 2019, 59, 102656 .
AMA StyleGiorgio Lo Iacono, Federica Gigli, Lorenzo Gherzi, Daniele Avenoso, Stefano Fiori, Giulia Sedda, Corrado Tarella, Lorenzo Spaggiari. Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis: A rare and life-treating condition. Transfusion and Apheresis Science. 2019; 59 (2):102656.
Chicago/Turabian StyleGiorgio Lo Iacono; Federica Gigli; Lorenzo Gherzi; Daniele Avenoso; Stefano Fiori; Giulia Sedda; Corrado Tarella; Lorenzo Spaggiari. 2019. "Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis: A rare and life-treating condition." Transfusion and Apheresis Science 59, no. 2: 102656.
Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. Challenges and innovations in personalized medicine care. Future Oncology 2019, 15, 3305 -3308.
AMA StyleGiulia Sedda, Roberto Gasparri, Lorenzo Spaggiari. Challenges and innovations in personalized medicine care. Future Oncology. 2019; 15 (29):3305-3308.
Chicago/Turabian StyleGiulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. 2019. "Challenges and innovations in personalized medicine care." Future Oncology 15, no. 29: 3305-3308.
The investigation of pleural lesions is challenging. Thoracoscopic pleural biopsies are often the chosen approach for diagnosis and, in case of malignancy, for disease staging and palliation pleurodesis. Minimally invasive techniques represent a valid option in patients that cannot undergo surgery, minimizing the risks related to more aggressive procedures. Here we report the case of a 63-year-old man with computed tomography evidence of paratracheal pleural thickening that was successfully sampled with endobronchial ultrasound-guided transbronchial needle aspiration. This technique should be considered for the diagnosis of pleural lesions adjacent to the main airway; it represents a safer, better tolerated, and less invasive alternative to operation.
Stefano Maria Donghi; Elena Prisciandaro; Giulia Sedda; Juliana Guarize; Lorenzo Spaggiari. When Less Is More: EBUS-TBNA for the Diagnosis of Pleural Lesions. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 2019, 14, 473 -475.
AMA StyleStefano Maria Donghi, Elena Prisciandaro, Giulia Sedda, Juliana Guarize, Lorenzo Spaggiari. When Less Is More: EBUS-TBNA for the Diagnosis of Pleural Lesions. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2019; 14 (5):473-475.
Chicago/Turabian StyleStefano Maria Donghi; Elena Prisciandaro; Giulia Sedda; Juliana Guarize; Lorenzo Spaggiari. 2019. "When Less Is More: EBUS-TBNA for the Diagnosis of Pleural Lesions." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 14, no. 5: 473-475.
Niccolò Filippi; Elena Prisciandaro; Juliana Guarize; Stefano Maria Donghi; Giulia Sedda; Lorenzo Spaggiari. One-shot diagnosis: EBUS-TBNA as a single procedure for thyroid, pulmonary and lymph nodal lesions. Advances in Respiratory Medicine 2019, 87, 194 -195.
AMA StyleNiccolò Filippi, Elena Prisciandaro, Juliana Guarize, Stefano Maria Donghi, Giulia Sedda, Lorenzo Spaggiari. One-shot diagnosis: EBUS-TBNA as a single procedure for thyroid, pulmonary and lymph nodal lesions. Advances in Respiratory Medicine. 2019; 87 (3):194-195.
Chicago/Turabian StyleNiccolò Filippi; Elena Prisciandaro; Juliana Guarize; Stefano Maria Donghi; Giulia Sedda; Lorenzo Spaggiari. 2019. "One-shot diagnosis: EBUS-TBNA as a single procedure for thyroid, pulmonary and lymph nodal lesions." Advances in Respiratory Medicine 87, no. 3: 194-195.
One of the main causes of the high mortality rate in lung cancer is the late-stage tumor detection. Early diagnosis is therefore essential to increase the chances of obtaining an effective treatment quickly thus increasing the survival rate. Current screening techniques are based on imaging, with low dose computed tomography (LDCT) as the pivotal approach. Even if LDCT has high accuracy, its invasiveness and high false positive rate limit its application to high risk population screening. A non-invasive, cost-efficient, and easy to use test should instead be designed as an alternative. Exhaled breath contains thousands of volatile organic compounds (VOCs). Since ancient times, it has been understood that changes in the VOCs mixture may be directly related to the presence of a disease, and recent studies have quantified the change in compounds' concentration. Analyzing exhaled breath to achieve lung cancer early diagnosis represents a non-invasive, low-cost, and user-friendly approach, thus being a promising candidate for high risk lung cancer population screening. This reviews discusses technological solutions that have been proposed in the literature as tools to analyze exhaled breath for lung cancer diagnosis, together with factors that potentially affect the outcome of the analysis. Even if research on this topic started many years ago, and many different technological approaches have been adopted, there is still no validated clinical application of this technique. Standard guidelines and protocols should be defined by the medical community in order to translate exhaled breath analysis to clinical practice.
Davide Marzorati; Luca Mainardi; Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari; Pietro Cerveri. A review of exhaled breath: a key role in lung cancer diagnosis. Journal of Breath Research 2019, 13, 034001 .
AMA StyleDavide Marzorati, Luca Mainardi, Giulia Sedda, Roberto Gasparri, Lorenzo Spaggiari, Pietro Cerveri. A review of exhaled breath: a key role in lung cancer diagnosis. Journal of Breath Research. 2019; 13 (3):034001.
Chicago/Turabian StyleDavide Marzorati; Luca Mainardi; Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari; Pietro Cerveri. 2019. "A review of exhaled breath: a key role in lung cancer diagnosis." Journal of Breath Research 13, no. 3: 034001.
Giulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. Comments on “Pilot Study: Detection of Gastric Cancer From Exhaled Air Analyzed With an Electronic Nose in Chinese Patients”. Surgical Innovation 2019, 26, 268 -269.
AMA StyleGiulia Sedda, Roberto Gasparri, Lorenzo Spaggiari. Comments on “Pilot Study: Detection of Gastric Cancer From Exhaled Air Analyzed With an Electronic Nose in Chinese Patients”. Surgical Innovation. 2019; 26 (2):268-269.
Chicago/Turabian StyleGiulia Sedda; Roberto Gasparri; Lorenzo Spaggiari. 2019. "Comments on “Pilot Study: Detection of Gastric Cancer From Exhaled Air Analyzed With an Electronic Nose in Chinese Patients”." Surgical Innovation 26, no. 2: 268-269.
Giulia Sedda; Roberto Gasparri. A new era in lung cancer care: from early diagnosis to personalized treatment. Shanghai Chest 2019, 3, 9 -9.
AMA StyleGiulia Sedda, Roberto Gasparri. A new era in lung cancer care: from early diagnosis to personalized treatment. Shanghai Chest. 2019; 3 ():9-9.
Chicago/Turabian StyleGiulia Sedda; Roberto Gasparri. 2019. "A new era in lung cancer care: from early diagnosis to personalized treatment." Shanghai Chest 3, no. : 9-9.